or Try an Advanced Search...

    Hematologic Malignancies Stocks List

    Symbol Grade Name % Change
    TCRX B TScan Therapeutics, Inc. 0.90
    SLS C SELLAS Life Sciences Group, Inc. -0.68
    PRTC C PureTech Health plc 0.00
    KYMR D Kymera Therapeutics, Inc. -1.83
    INMB D INmune Bio Inc. -2.86
    INCY D Incyte Corporation 0.42
    HOWL F Werewolf Therapeutics, Inc. -3.28
    FATE F Fate Therapeutics, Inc. -5.80
    CRBU F Caribou Biosciences, Inc. -5.57
    CLLS C Cellectis S.A. -1.64
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Solid Tumors Biotechnology Cancer Life Sciences Clinical Medicine Immune System Immunology Medicine Tumors Of The Hematopoietic And Lymphoid Tissues Acute Myeloid Leukemia Biology CD19 Cancer Immunotherapy Cancer Treatment Health Sciences Hematopoietic Stem Cell Leukemia Multiple Myeloma Acute Lymphoblastic Leukemia

    Related ETFs - A few ETFs which own one or more of the above listed Hematologic Malignancies stocks.

    Symbol Grade Name Weight
    SURI D Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 7.52
    IWC B iShares Microcap ETF 0.06
    VXF B Vanguard Extended Market ETF 0.0
    View all Hematologic Malignancies ETFs...
    Compare ETFs
    Compare IWC to VXF Compare SURI to IWC Compare SURI to VXF

        Hematologic Malignancies Stocks Recent News

        Date Stock Title
        May 17 INCY Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week
        May 16 CRBU Expert Ratings For Caribou Biosciences
        May 16 FATE Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
        May 14 INCY Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
        May 14 SLS SELLAS Life Sciences GAAP EPS of -$0.21
        May 14 SLS SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
        May 14 KYMR Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
        May 14 INCY Company News For May 14, 2024
        May 14 TCRX TScan Therapeutics First Quarter 2024 Earnings: Misses Expectations
        May 14 INCY Heard on the Street Monday Recap: Hello Kitty
        May 13 INCY Health Care Roundup: Market Talk
        May 13 INCY Tech Stocks Inch Higher Ahead Of Key Inflation Data, GameStop Skyrockets, Tencent Fuels China Rally: What's Driving Markets Monday?
        May 13 INCY Incyte Stock Marks Biggest Jump in 7 Years on ‘Dutch Auction’ Buyback Plan. How It Works.
        May 13 FATE Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript
        May 13 TCRX TScan Therapeutics GAAP EPS of -$0.32, revenue of $0.56M
        May 13 INCY Incyte Launches $1.67 Billion Share Repurchase 'Dutch Auction' Tender Offer; to Buy Back $328 Million of Baker Entities' Shares
        May 13 TCRX TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
        May 13 INCY Incyte jumps 6%, intends to buy back $2B stock
        May 13 TCRX Key Takeaways From TScan Therapeutics Analyst Ratings
        May 13 INCY Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
        Related Industries: Biotechnology
        Related Stock Lists: Cancer Solid Tumors Acute Myeloid Leukemia Antineoplastic Drugs Biopharmaceutical Breast Cancer Cancer Treatment Clinical Medicine Endometrial Cancer Gynaecological Cancer Gynaecology Health Care Immune System Immunology Immunotherapies Life Sciences Novel Cancer Oncology Oncolytics Biotech Ovarian And Endometrial Cancers
        Hematologic Malignancies

        Hematologic malignancies are cancers of the blood, bone marrow, and lymphatic system. These cancers can affect the production and function of blood cells, leading to a variety of symptoms and complications. Common types of hematologic malignancies include leukemia, lymphoma, and multiple myeloma. Treatment for hematologic malignancies may include chemotherapy, radiation therapy, stem cell transplant, and targeted therapy.

        Browse All Tags